QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer
28 avr. 2022 07h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 28, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Announces Reverse Stock Split Effective March 10, 2022
09 mars 2022 16h30 HE
|
QSAM Biosciences Inc.
Austin, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (the “Company”) (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including...
QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
02 févr. 2022 08h30 HE
|
QSAM Biosciences Inc.
Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
11 août 2021 09h00 HE
|
QSAM Biosciences Inc.
Palm Beach, FL, Aug. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the...
QSAM Biosciences Issues Letter from CEO on Successful First Quarter 2021
25 mai 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, May 25, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today: Dear...
QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA
04 mai 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, May 04, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
QSAM Biosciences Appoints Richard K. Burt, M.D., Pioneer in the Use of Stem Cell Transplants to Treat Autoimmune Diseases, to Scientific Board of Advisors
28 avr. 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company
19 avr. 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 19, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today: Dear...
QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
17 mars 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the...
QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
16 févr. 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, Feb. 16, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...